Granules India witnessed a block deal worth ₹1,160 crore as promoter Krishna Prasad Chigurupati reduced his stake. About 5.3% of the company’s equity changed hands at a discount to the previous closing price. While large promoter sales can create temporary supply pressure, the company has recently shown strong financial performance with significant growth in profit and revenue.
Granules India saw significant trading activity on September 11, 2026, as 1.33 crore shares changed hands in a block deal window. The transaction, valued at approximately ₹1,160 crore, was executed at a price of ₹872.50 per share. This price was roughly 3% lower than the stock's closing price of ₹899.25 on the previous day.
The seller is identified as promoter Krishna Prasad Chigurupati. As of the end of the June 2026 quarter, Chigurupati held approximately 31% of the company. This sale aligns with market reports indicating a plan to reduce his stake by up to 6.94%, or 1.72 crore shares. A key factor for shareholders is the 180-day lock-in period attached to the deal, which prevents the promoter from selling further shares during this time. This provides the market with clarity regarding the potential supply of shares for the next six months.
The stake sale occurs against a backdrop of strong financial growth for the pharmaceutical company. In the first quarter of the 2027 fiscal year, Granules India reported a 60% year-on-year jump in net profit, reaching ₹179.96 crore. Revenue also rose by 22% to ₹1,476.8 crore. The company’s business model is shifting toward higher-value products, with complex generics now accounting for 50% of its finished dosage sales, up from 39% in the same period last year. Operational margins also remained healthy, with an EBITDA margin of 22.9%.
Before this sale, Granules India stock had performed strongly in 2026, rising about 45% by Thursday's close. Large promoter stake sales can sometimes weigh on share prices in the short term because they increase the immediate supply of shares available in the market. However, such deals can also lead to higher institutional ownership if long-term investors step in to purchase the shares, potentially increasing the company's free float, which is the portion of shares available for the public to trade.
Moving forward, the primary monitorables for investors will be whether the company can maintain its current momentum in the complex generics segment and if the improved liquidity helps in better price discovery for the stock. Market participants will also track whether the operational margins remain stable as the company continues its expansion efforts.